Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach.
about
In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory ApproachesCharacterization of respiratory drug delivery with enhanced condensational growth using an individual path model of the entire tracheobronchial airwaysEvaluation and modification of commercial dry powder inhalers for the aerosolization of a submicrometer excipient enhanced growth (EEG) formulationImproving the lung delivery of nasally administered aerosols during noninvasive ventilation-an application of enhanced condensational growth (ECG)High-efficiency generation and delivery of aerosols through nasal cannula during noninvasive ventilationTargeting aerosol deposition to and within the lung airways using excipient enhanced growthEvaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial modelDrug-targeting methodologies with applications: A reviewA novel micropump droplet generator for aerosol drug delivery: Design simulationsValidating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo DataDevelopment of characteristic upper tracheobronchial airway models for testing pharmaceutical aerosol deliveryOptimal delivery of aerosols to infants during mechanical ventilation.Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devicesNumerical Model to Characterize the Size Increase of Combination Drug and Hygroscopic Excipient Nanoparticle AerosolsIn silico models of aerosol delivery to the respiratory tract - development and applications.Condensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: comparison of CFD predictions with experimental resultsProduction of Inhalable Submicrometer Aerosols from Conventional Mesh Nebulizers for Improved Respiratory Drug DeliveryCondensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: evaluation of formulation and delivery device.Performance of combination drug and hygroscopic excipient submicrometer particles from a softmist inhaler in a characteristic model of the airways.Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs.Improving pharmaceutical aerosol delivery during noninvasive ventilation: effects of streamlined components.Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols.Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations.The use of computational fluid dynamics in inhaler design.The function and performance of aqueous aerosol devices for inhalation therapy.Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways.Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.Small Airway Absorption and Microdosimetry of Inhaled Corticosteroid Particles after Deposition.Particle transport in the human respiratory tract: formulation of a nodal inverse distance weighted Eulerian-Lagrangian transport and implementation of the Wind-Kessel algorithm for an oral delivery.Recommendations for Simulating Microparticle Deposition at Conditions Similar to the Upper Airways with Two-Equation Turbulence ModelsThe influence of lung volume during imaging on CFD within realistic airway modelsMicroparticle Transport and Deposition in the Human Oral Airway: Toward the Smart SpacerCFD Modeling of Spray Atomization for a Nasal Spray DeviceDevelopment of a Stochastic Individual Path (SIP) Model for Predicting the Deposition of Pharmaceutical Aerosols: Effects of Turbulence, Polydisperse Aerosol Size, and Evaluation of Multiple Lung Lobes
P2860
Q28080832-AF9C8D70-E6BE-454C-9441-5DAC42CC2A0BQ28386376-AC6D337C-E22B-42D2-AAA7-0C7F7B04E8ECQ28387314-E4C8D4DF-E007-48A8-A160-C9792FB38E68Q28389833-93CA64C9-304F-4B6F-953D-C5789756B66CQ28390968-0861B562-8ABC-4D2A-BE81-1A74BEED07D2Q28390979-E7FBBA50-5BCB-4F93-92EC-1BE01B8F4DAAQ28397573-6DDB65BF-4027-42A1-8C64-B965CAF98C66Q28649786-C63919F3-2B36-42B0-A5A9-1BF5C9200ACFQ30478200-1CFA4807-6EB3-4BF3-B042-08693255B6BCQ30945192-39534A84-D0BF-4103-BD0A-4E6EF8397E91Q33626905-AC716BCA-783F-48E8-8248-EAAC46E10DFEQ34488035-56840AAF-77C5-416E-A740-476DF1C50ABEQ34721292-5BAE65C9-0AC2-4B92-AECE-9D342B9895F7Q35127772-E9A8E8B4-5D7F-44F4-A0A0-A8113D0AC162Q35673202-C590AAE3-4062-4E1F-8FAF-8CC153DCF56EQ35784530-874A6834-40CE-4A40-84CE-EC45B0764B05Q36029582-5AF5D823-80A6-4B5C-9F97-3880B10B5192Q36165365-F0948361-D393-46CD-9CED-CCD371BFAC6BQ36417205-CE4FD823-2C6E-4B88-B2D3-E396459FEEA4Q36559720-BF7774D7-16DB-4452-B8A0-E3534652BFE7Q36824193-17BCB171-2C22-40F2-B2E4-5C2FE5205C74Q36989479-769751C3-42D1-4F2F-BC00-52646F03CB5AQ37626575-842F7756-2CF8-427A-9B28-76F0277BF844Q38071652-4231F710-0E41-4128-8195-8879868D1481Q38803035-9A6DAD05-5585-4BA4-8F29-34B0015A1EFBQ39658347-C33391B7-F374-4AC7-841E-748B8E70DE1BQ39848034-73EB044B-A51D-4FC2-96A0-DA7A1FF1EAAEQ45061912-00501596-4932-48EB-BC91-BB50F52939FCQ50861783-D566F119-DF16-40C9-B305-3A8E459BBEC4Q57825732-0493762F-7F16-4821-A3A8-26819DAC5A01Q58094787-84BBCF71-6FBF-49EE-8D36-DED4C73D63D3Q58095240-ADCF5D9E-D369-4816-AF9E-6A50B774C6CAQ58096197-6E1215A1-FA2F-44CF-80FE-2D6B86729596Q58303971-8D22F3CA-802D-45BF-925C-76F0C9440FC2
P2860
Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Evaluation of the Respimat Sof ...... ent CFD and in vitro approach.
@ast
Evaluation of the Respimat Sof ...... ent CFD and in vitro approach.
@en
type
label
Evaluation of the Respimat Sof ...... ent CFD and in vitro approach.
@ast
Evaluation of the Respimat Sof ...... ent CFD and in vitro approach.
@en
prefLabel
Evaluation of the Respimat Sof ...... ent CFD and in vitro approach.
@ast
Evaluation of the Respimat Sof ...... ent CFD and in vitro approach.
@en
P356
P1476
Evaluation of the Respimat Sof ...... ent CFD and in vitro approach.
@en
P2093
P Worth Longest
P304
P356
10.1089/JAMP.2008.0708
P577
2009-06-01T00:00:00Z